The DropJune 30, 2026via Financial Times Technology
Anthropic launches Claude Science in push for pharma revenue
Why it matters
Anthropic is moving beyond consumer/enterprise chat into vertical-specific AI products, targeting high-margin pharma and biotech workflows. This signals a strategic pivot to defensible, domain-locked revenue streams—and a direct counter to OpenAI's enterprise playbook.
Key signals
- Claude Science product launch targeting pharma/biotech
- Use cases: 3D protein structure rendering, drug discovery workflows
- Vertical-specific product strategy (distinct from general-purpose Claude)
- Pharma revenue diversification play for Anthropic
The hook
Anthropic just shipped Claude Science. Pharma is the new revenue battleground.
New AI product has use cases in rendering 3D protein structures and drug discovery